William Blair analyst Myles Minter has reiterated their bullish stance on XENE stock, giving a Buy rating on April 27.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Myles Minter has given his Buy rating due to a combination of factors centered on Xenon’s lead candidate, azetukalner, and its potential in focal onset seizure epilepsy. He highlights the robust seizure-reduction data in a difficult-to-treat population and emphasizes that the simple once-daily, single-pill regimen without titration or major drug interactions should support broad adoption among neurologists and epileptologists.
Minter also notes that azetukalner’s profile positions it as a compelling branded antiseizure medication with blockbuster potential, especially when compared with peers targeting the same indication. In addition, he points to upside from Xenon’s earlier-stage pain franchise and Nav1.7 program, arguing these assets add meaningful optionality beyond azetukalner, and his updated sum-of-the-parts valuation supports materially higher share levels, justifying his Outperform/Buy stance.
In another report released on April 27, Stifel Nicolaus also maintained a Buy rating on the stock with a $89.00 price target.